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Objective: Clinical trials have long been considered the ‘gold standard’ of research generated evidence in
health care. Patient recruitment is an important determinant in the success of the trials, yet little focus is
placed on the decision making process of patients towards recruitment. Our objective was to identify the
key factors pertaining to patient participation in clinical trials, to better understand the identiﬁed low
participation rate of patients in one clinical research facility within Ireland.
Design: Narrative literature review of studies focussing on factors which may act to facilitate or deter
patient participation in clinical trials. Studies were identiﬁed from Medline, PubMed, Cochrane Library
and CINAHL.
Results: Sixty-one studies were included in the narrative review: Forty-eight of these papers focused
speciﬁcally on the patient's perspective of participating in clinical trials. The remaining thirteen related
to carers, family and health care professional perspectives of participation. The primary factor inﬂuencing
participation in clinical trials amongst patients was related to personal factors and these were collec-
tively associated with obtaining a form of personal gain through participation. Cancer was identiﬁed as
the leading disease entity included in clinical trials followed by HIV and cardiovascular disease.
Conclusion: The vast majority of literature relating to participation in clinical trials emanates predomi-
nantly from high income countries, with 63% originating from the USA. No studies for inclusion in this
review were identiﬁed from low income or developing countries and therefore limits the generalizability
of the inﬂuencing factors.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Clinical trials, in which humans are prospectively assigned to
one or more health-related interventions to evaluate the effects on
health outcomes have long been considered the ‘gold standard’ of
research generated evidence in health care. Clinical trials in key
disease groups including the effectiveness of prevention strategies,
early detection and treatment interventions for cancer [1], and the
diagnosis, treatment, and prevention of chronic diseases [2] are
among the most common areas where clinical trials are under-
taken. During 2013e2014, one clinical research facility within
Ireland had a total of ﬁfty-six such trials in progress with a patienton Harmonisation Guidelines
d Clinical Experience; RCT,
erica.
Inc. This is an open access article uuptake of 291. The geographical region in which the clinical
research facility is located has a catchment of 1,000,000 people
with approximately 250,000 patients being treated in the associ-
ated hospitals per year. Thus the number of participants involved in
clinical trials at this facility represented less than half of one
percent of the patient population being treated. The extremely
small numbers of clinical trial participants at this centre raised
questions as to the potential factors which may be acting as de-
terrents to patient participation in clinical trials, and how such
factors may be addressed to improve participation rates.
To address this issue and aid the sites in developing more
effective recruitment procedures that encourage participation in
clinical trials [3], a limited narrative literature review was under-
taken to identify factors inﬂuencing the participation of patients in
clinical trials.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Search strategy
A pragmatic approach to conducting the literature search was
adopted inﬂuenced by an absence of research funding and limited
time in which to undertake the study. A search on the three most
appropriate key search terms; i) patient participation ii) clinical
trials and iii) factors was undertaken. Search limitations were i)
English language, ii) humans and iii) publication period e with
publications between 2003 and 2014 being included in the review
and iv) restriction to free full text availability - this restriction
related to an absence of funding for the review. Databases searched
included Medline, PubMed, Cochrane Library and CINAHL. These
four databases were selected as theywere the databases considered
most appropriate to this study.
This phase of the search identiﬁed a total of 429 potential
publications. Following initial review of all titles and abstracts of
identiﬁed publications by researcher one (EW), 100 were identiﬁed
as relevant to this study based on the following inclusion criteria; i)
study identiﬁable as a clinical trial; participants were human adults
over 18 years of age; papers identiﬁed factors which had potential
to inﬂuence participation of patients in clinical trials.
2.2. Data extraction and management
Following initial review, a total of 100 publications were iden-
tiﬁed as potentially relevant for inclusion based on the criteria
outlined above. The 100 articles were read in full and their rele-
vance assessed, resulting in a total of sixty-one papers being
identiﬁed as relevant for inclusion in this review. A total of thirty
nine papers were excluded; twelve were identiﬁed as duplicates,
eighteen examined participants who did not meet eligibility
criteria relating to age; seven were not related to clinical trials; one
examined a pattern of participation but was of no relevance and
one was a published pilot study. The sixty-one articles selected for
inclusion represented clinical trials in a variety of clinical settings
utilising methods to increase patient recruitment onto healthcare
studies and hypothetical trials. Forty-eight of these papers focused
speciﬁcally on the patient's perspective of participating in clinical
trials, including twelve randomized control trials (RCT) or hypo-
thetical trials. The remaining thirteen related to carers, family and
health care professional perspectives of participation.
3. Results
The vast majority of papers identiﬁed, 63% (n ¼ 39), emanated
from the United States of America (USA). Other countries repre-
sented included Asia, Australia, Canada, Europe and South America.
A total of eight papers, representing 9% of the total identiﬁed,
originated from Europe and of these, the majority (n ¼ 6) were
undertaken in the United Kingdom (UK). While no studies relating
to participation in clinical trials conducted within an Irish context
were identiﬁed, the past decade in Ireland haswitnessed increasing
emphasis in funding health research with the Irish Health Research
Board, the principal funding body for health research, investing
V100 million in building clinical research infrastructure with the
majority of this infrastructure focused on undertaking clinical trials
[4]. Thus the timing of this paper is relevant in contributing to a
better understanding of the factors which contribute to patient
participation in clinical trials.
Cancer was identiﬁed as the leading disease entity included in
clinical trials followed by HIV and cardiovascular disease. The dis-
tribution of disease range for the identiﬁed studies is demonstrated
in Fig. 1. The review identiﬁed the key factors pertaining to patientparticipation in clinical trials and the primary factor associated
with a decision to participate in a clinical trial related to personal
factors. Secondary factors identiﬁed were cost, altruism, commu-
nication, physician inﬂuence, research process and demographicse
see Fig. 2. These key factors identiﬁed form the basis of the
remainder of this paper.
3.1. Personal factors
The primary reasons that people committed to participating in a
clinical trial were personal and critical to this was an expectation of
some form of personal gain. However, as White and Hardy [5]
identify, perceived personal gain is one among a number of moti-
vational factors which together inﬂuence participation. Perceived
personal gain, rather than being the singular inﬂuencing factor is
likely mediated by other factors including the perception of per-
sonal risk and fear. As identiﬁed above, no studies conducted in
Ireland were identiﬁed in this search. While the Irish health system
differs signiﬁcantly to that of the USA, other European countries
and to a lesser extent that of the UK, and that these structural and
funding differences are likely to impact participation of patients in
clinical trials, it is also likely that signiﬁcant similarities in terms of
the factors which both encourage and deter clinical trial partici-
pation exist, particularly in areas of personal and altruistic
motivation.
3.2. Personal gain
A total of 12 studies identiﬁed that clinical trial participants
perceived they received better care and extra attention when
partaking in clinical trials [6e11] (see Table 1). The perception that
participating in a clinical trial results in better care and extra
attention is likely to be related to the nature and frequency of
interaction with trial procedures which require stringent surveil-
lance and monitoring to ensure adherence to trial protocols [12] as
well as access to new treatments which, from the participants
perspective, may be potentially more beneﬁcial than existing
treatments. Within oncology settings, while there is recognition
that the chances of obtaining a personal cure areminimal, the belief
that taking part in the clinical trial may result in eventual beneﬁts
to others, provides participants with a sense of purpose and hope
[6,8,13]. Furthermore, exercising and maintaining personal auton-
omy [14] by having a say in care, an opportunity to improve the
quality of their life with the concomitant impact on lifestyle [15]
have also been identiﬁed as inﬂuential.
The desire to improve personal health as a motivating factor
inﬂuencing clinical trial participation was reported in nine studies.
Gaining access to health care was among the key factors associated
with the desire to improve health and this was of particular rele-
vance in studies undertaken in the USA where agreement to
participate in clinical trials could provide access to health care
which would not otherwise be available to the person due to lack of
health insurance. A GRACE (Gender, Race And Clinical Experience)
trial identiﬁed participation in clinical trials was motivated by
participants gaining access to treatment (33%) and altruism or the
belief that participation enabled others to be helped (36%) [16].
3.3. Personal risk
3.3.1. Personal risk and fear
The perception of personal risk and fear were two interrelated
but distinguishable constructs identiﬁed in this review as being
important in decision to participate in clinical trials. Perceiving a
risk to self was identiﬁed as the principal reason why people made
a decision not to participate in clinical trials. Linked to this
Fig. 1. Distribution of disease range for all studies.
Fig. 2. Key factors pertaining to patient participation.
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by the actual or perceived threat of danger or harm [17] resulting
from participation in a clinical trial. Personal risk and feeling fearful
were related to side effects of trial intervention or treatments along
with the possibility of trial treatments interacting with existing
treatments. Feeling fearful ranged from fear brought about by the
procedures required within the clinical trial [18], fear about the
nature of the research process [9] and fear about being cut off from
family if conﬁdentiality about trial participationwas broken [19]. In
the studies identifying personal risk of unconﬁrmed treatment and
perception of its severity leading to participants declining, four
focused on HIV and high risk of HIV, and reported that the stigma
associated with the disease was a contributory factor to non-
participation [18e20]. Fear of the treatment and the possibility of
it being ineffective [11] was also evident among participants and
physicians. Further causes for non-participation due to personal
risk included patients having to take medications [6,21], the
impression that participation required signing ‘their life away’ [22],
and being treated by an unknown physician when taking part in a
trial [23].
However, increased interactionwith trial staff and the improved
level of information and understanding of the trial was identiﬁed as
working to reduce fear and improve likelihood of participation.
Thus while fear was identiﬁed as a critical factor deterringparticipation, there is evidence that this can be mitigated by
research staff providing potential participants with adequate
reassurance and detailed explanations of the procedural elements
of the trial.
Associated with perceptions of personal risk and fear was the
perception that engaging in a trial and taking medications or other
interventions as yet untested or unproven to result in a positive
outcome, was the perception of being experimented upon and this
was a further important factor in declining participation. Seven of
the studies within this review identiﬁed that unconﬁrmed treat-
ment and the perception of its severity was inﬂuential in partici-
pants declining to enter clinical trials [23e25]. Other participants
refused to enter because they viewed clinical trials as being inva-
sive [5]. While evidence from clinical trials may result in conﬁr-
mation of treatment efﬁcacy, cases where the disease is resistant to
the particular treatment type or where individual participants are
severely impacted by adverse effects of treatment can result in non-
participation or discontinuation. Thus the in the absence of a
guarantee that the trial intervention will be effective in an indi-
vidual case was for some potential participants a deterrent.
It is anticipated that fear and personal risks would have similar
effects on patient participation within clinical trials in Ireland as
they would worldwide, however it is possible that these percep-
tions may be heightened due to clinical trials not being as widely
recognised within Ireland as they are in other countries such as
USA.3.3.2. Research process
This review identiﬁed variables relating to the clinical trials
process as inﬂuential in patient's decision to participate. These
were categorised under the umbrella term research process, which
refers to any activities that are undertaken speciﬁcally for the
clinical trial. The research process was discussed twenty eight times
throughout this reviewed literature, accounting for an overall re-
ported inﬂuence of 8% (Fig. 2). The main inﬂuencing factor of the
research process is the trial designwith 99% of the studies reviewed
referring to it as a factor discouraging participation [5,9,14,26e29].
Patients are more inclined towards non-participation due to the
stringent nature of the clinical trials protocols [27,28]. From the
patient perspective, whether based in USA, Europe or Ireland, it is
likely that such protocols appear overly strict. Since clinical trials
are experimental processes utilising new and as yet unproven
drugs or procedures in human beings, stringent practices are
Table 1
Inﬂuencing and deterring factors for clinical trial participation.
Participation
Factors Studies
Perceived better care Carroll et al., 2012; Meneguin and Cesar, 2012; Tallon et al., 2011; Truong et al., 2011; Wang et al., 2011; Voytek, Jones and Metzger, 2011;
Biedrzycki, 2010; White and Hardy, 2010; Kasner et al., 2009; Costenbader et al., 2007; Sharp et al., 2006, Zullino et al., 2003
Improve personal health Brubaker et al., 2013; Squires et al., 2013; Biedrzycki, 2010; Houlihan et al., 2010; Udrea et al., 2009; Gadegbeku et al., 2008; Davison et al.,
2007; Townsley et al., 2006; Borrayo, Lawsin and Coit, 2005
Personal beneﬁts Meneguin and Cesar, 2012; Voytek, Jones and Metzger, 2011; Biedrzycki, 2010; White and Hardy, 2010; Costenbader et al., 2007
Physician inﬂuence Brubaker et al., 2013; Sprague et al., 2013; Lee et al., 2012; Meneguin and Cesar, 2012, McMahon et al., 2011; Tallon et al., 2011; Houlihan et al.,
2010; Kohara and Inoue, 2010; Sabesan et al., 2010; Kinder et al., 2010; Costenbader et al., 2007; Townsley et al., 2006; Borrayo, Lawsin and
Coit, 2005; Sahay et al., 2004; Brown and Topcu, 2003; Zullino et al., 2003
Altruism Brubaker et al., 2013; Squires et al., 2013; Chakrapani et al., 2012; Meneguin and Cesar, 2012; Rooney et al., 2011; Tallon et al., 2011; Troung
et al., 2011; Sabesan et al., 2010; Kasner et al., 2009; Udrea et al., 2009; Gadegbeku et al., 2008; Moutsiakis and Chin, 2007; Townsley et al.,
2006; Sharp et al., 2006
Fight Stigma Chakrapani et al., 2012
Physician
recommendation
Houlihan et al., 2010; Kinder et al., 2010; Costenbader et al., 2007 Sahay et al., 2004; Brown and Topcu, 2003
Relevant adequate
information
Biedrzycki, 2010
Insurance cover Sahay et al., 2004; Brown and Topcu, 2003
Financial reward/
incentive/cost
Brubaker et al., 2013; Carroll et al., 2012; Lee et al., 2012; Darnell, McGuire and Danner, 2011; Menezes et al., 2011; Rooney et al., 2011; Voytek,
Jones and Metzger, 2011; Holman et al., 2010; Kasner et al., 2009; Udrea et al., 2009, Costenbader et al., 2007; Baquet et al., 2006; Sahay et al.,
2005; Tu et al., 2005; Brown and Topcu, 2003; Zullino et al., 2003
Medical cost White and Hardy, 2010; Udrea et al., 2009; Zullino et al., 2003
Flexibility Rooney et al., 2011; Tallon et al., 2011, Sharp et al., 2006
Transport provided Baquet et al., 2006
Information on
newsletter
Udrea et al., 2009; Townsley et al., 2006; Sahay et al., 2005
Relevant language Rooney et al., 2011; Tu et al., 2005
Non participation
Factors Studies
Perceived personal risk Brubaker et al., 2013; Martin et al., 2013; Chakrapani et al., 2012; McMahon et al., 2011, Rooney et al., 2011; Tallon et al., 2011; Voytek,
Jones and Metzger, 2011; Biedrzycki, 2010; Kinder et al., 2010; White and Hardy, 2010; Udrea et al., 2009; Gadegbeku et al., 2008;
Moutsiakis and Chin, 2007; Costenbader et al., 2007; Hussain-Gambles, Atkin and Leese, 2006; Costenbader et al., 2005; Zullino et al.,
2003
Adverse effects of treatment Brubaker et al., 2013, Wang et al., 2011; Sahay et al., 2005
Guinea pig/Lab Rat McMahon et al., 2011; Wang et al., 2011; Sabesan et al., 2010; Gadegbeku et al., 2008; Costenbader et al., 2005; Tu et al., 2005; Zullino
et al., 2003
Cost McMahon et al., 2011; Kinder et al., 2010; Gadegbeku et al., 2008; Hussain-Gambles, Atkin and Leese, 2006; Sharp et al., 2006
Time commitment/cost Brubaker et al., 2013; Carroll et al., 2012; Lee et al., 2012; Houlihan et al., 2011; McMahon et al., 2011; Rooney et al., 2011; Kinder et al.,
2010; Kasner et al., 2009; Gadegbeku et al., 2008; Baquet et al., 2006; Sharp et al., 2006; Zullino et al., 2003
Stigma Chakrapani et al., 2012; Rooney et al., 2011
Questionnaires Houlihan et al., 2010; Tallon et al., 2011
Research process Martin et al., 2013; McMahon et al., 2011; Houlihan et al., 2010; Kinder et al., 2010; White and Hardy, 2010; Kasner et al., 2009;
Costenbader et al., 2007
Allocation of placebo/
randomisation
Martin et al., 2013; Brubaker et al., 2013; Kinder et al., 2010; Kasner et al., 2009, udrea
Fear Chakrapani et al., 2012; Kasner et al., 2009; Sahay et al., 2004; Zullino et al., 2003
Side effects Brubaker et al., 2013; Martin et al., 2013; Chakrapani et al., 2012; McMahon et al., 2011, Rooney et al., 2011; Tallon et al., 2011; Voytek,
Jones and Metzger, 2011; Biedrzycki, 2010; Kinder et al., 2010; White and Hardy, 2010; Udrea et al., 2009; Gadegbeku et al., 2008;
Moutsiakis and Chin, 2007; Costenbader et al., 2007; Hussain-Gambles, Atkin and Leese, 2006; Costenbader et al., 2005; Zullino et al.,
2003
Signing life away Darnell, McGuire and Danner, 2011
Decreased quality of life McMahon et al., 2011; Sabesan et al., 2010
Language barriers Rooney et al., 2011; Cooke et al., 2010; Hussain-Gambles, Atkin and Leese, 2006; Borrayo, Lawsin and Coit, 2005; Tu et al., 2005
Lack of understanding Townsley et al., 2006; Smith et al. (2007)
Misconceptions Chakrapani et al., 2012; Dhalla and Poole, 2011; Darnell, McGuire and Danner, 2011; Sabesan et al., 2010; Borrayo, Lawsin and Coit,
2005; Tu et al., 2005
Work absence Kinder et al. 2010; Sharp et al., 2006
Severe treatment/unconﬁrmed
treatment
Brubaker et al., 2013; Chakrapani et al., 2012; Lee et al., 2012; Menezes et al., 2011; Sabesan et al., 2010; Moutsiakis and Chin, 2007;
Sahay et al., 2005
Arrange transport Martin et al., 2013; Kinder et al., 2010
Unconﬁrmed treatment/severity of
treatment
Brubaker et al., 2013; Chakrapani et al., 2012; Lee et al., 2012; Sabesan et al., 2010; Moutsiakis and Chin, 2007; Borrayo, Lawsin and
Coit, 2005; Sahay et al., 2005
Taking medication Carroll et al., 2012; Borrayo, Lawsin and Coit, 2005
Unknown physician Brubaker et al., 2013
Visual/audial impairment Goode et al., 2008
Inability to consent Cooke et al., 2010
Threat to health Borrayo, Lawsin and Coit, 2005
Last option Tu et al., 2005
Childcare cost Baquet et al., 2006; Sahay et al., 2004
Insurance cover cost Biedrzycki, 2010
Media cover Lee et al., 2012
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Table 1 (continued )
Non participation
Factors Studies
Physician inﬂuence Brubaker et al., 2013; Sprague et al., 2013; Lee et al., 2012; Meneguin and Cesar, 2012, McMahon et al., 2011; Tallon et al., 2011;
Houlihan et al., 2010; Kohara and Inoue, 2010; Sabesan et al., 2010; Kinder et al., 2010; Costenbader et al., 2007; Townsley et al., 2006;
Borrayo, Lawsin and Coit, 2005; Sahay et al., 2004; Brown and Topcu, 2003; Zullino et al., 2003
Physician recommendation McMahon et al., 2011; Sabesan et al., 2010; Zullino et al., 2003
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to study participants. However patients participating in clinical
trials may not always fully appreciate that such protocols are
required to protect patient safety. Protocols that require regular and
stringent monitoring of participants necessitating frequent hospital
visits are cited as a reason to decline participation [24] as are the
frequency of medical consultations [30], the time spent within
hospital [9] and the duration of the trial [6,9]. Other trial re-
quirements including the randomisation process, including the risk
of being randomised to the control arm of the study and receiving
placebo [5,9,14,26,29], having to complete questionnaires [7,28]
and keeping a diary log [28] are also noted as research process
barriers to participation.3.3.3. Cost
Cost was the second leading factor inﬂuencing the decision to
participate in clinical trials and was identiﬁed by sixteen studies.
Three constituents of cost identiﬁed in this review included i)
ﬁnancial cost, ii) medical cost and iii) time cost.3.3.4. Financial cost
Financial cost was identiﬁed in this review as the most inﬂu-
ential element of cost consisting of receiving an incentive or
ﬁnancial reward, the greatest inﬂuencing factor within the litera-
ture is incentive or ﬁnancial reward. Eight of the studies included in
this review provided an incentive to participants to engage in the
clinical trial and these consisted of a 12.5-megabyte jump drive;
entry to a free gift rafﬂe; $20 cash; two public transportation to-
kens, and a $20 gift certiﬁcate.While the use of incentives, ﬁnancial
and beneﬁt in kind, are identiﬁed as a factor inﬂuencing partici-
pation in clinical trials, evidence also exists to suggest that
providing ﬁnancial incentives alone do not guarantee entry to or
completion by participants of clinical trials. A study undertaken by
Stock [31], examined if providing a monetary incentive increased
attendance. No difference between the group receiving a $25
shopping voucher and those receiving no incentive was identiﬁed.
In a separate study, Holman [32] examined retention rates in pa-
tients participating in an RCT using a placebo. They identiﬁed that
while incentives such as a payment did constitute an inﬂuencing
factor in participation, it was the factor considered least important
by participants. It should also be noted that approximately half of
the studies utilising ﬁnancial incentives were undertaken in the
USA where such provision is legal. In Ireland, the use of incentives
for patient participation in research and speciﬁcally clinical trials is
governed by the International Conference on Harmonisation
Guidelines for Good Clinical Practice (ICH GCP, [33]), and use of
such incentives are rare and are generally associated with defraying
costs incurred by participation in the trial. A number of studies have
identiﬁed that a signiﬁcant cost related barrier to participation in
clinical trials is the ﬁnancial burden associated with trial partici-
pation [14,18,34,35]. In particular, the loss of income resulting from
work absence, and the costs of child care are of particular concern
to potential participants. This review identiﬁed that proximity of
the study and income level inﬂuenced clinical trial participation.Potential participants were more likely to participate if the location
of the research unit was in close proximity to where they lived [26]
and were less likely to participate if they lived in rural locations
distant from the trial centre [27,34]. Likewise income level was
viewed as a predictor for patient participation in clinical trials [35]
and having a greater income status was more likely to lead to a
higher chance of participation [36,37]. However, employment was
seen as a more reliable predictor than income [38]. It is possible
that those not employed were more likely to participate, as the
need to take time off work and losing income to participate was not
a factor.3.3.5. Medical cost
Medical Insurance cover overlapped ﬁnancial cost and medical
cost. While most frequently identiﬁed as a cost barrier [39], two
studies, Sahay [18] and Brown and Topcu [36] identify medical
insurance cover as a motivational and incentivising factor. Refer-
ence to medical cost as a barrier was primarily identiﬁed in studies
undertaken in the USA and this is likely to be related to the
requirement in the USA necessitating patients to be in possession of
health insurance to enable them to receive healthcare and to
participate in clinical trials. In contrast the current organisation of
the Irish health care system is broadly based on a welfare model
whereby citizens are not required to have private health insurance
to enable access to health care. While patients are responsible to
meet some costs associated with receipt of health care, this is based
on the citizens ability to pay, thus those on low income, in receipt of
unemployment beneﬁt, social welfare or other state related bene-
ﬁts such as disability beneﬁt will receive health care free of charge.
Thus, within the USA context participation in clinical trials is likely
to be signiﬁcantly inﬂuenced by the involvement of those who
would otherwise not have access to health care. When participants
agree to take part in clinical trials, they are according to Menezes
[40] likely to attain improved health status gaining access to free
investigative procedure such as blood testing and other in-
vestigations [41] without incurring ﬁnancial costs. By contrast, the
availability of free health care to Irish citizens who are unable to pay
is likely to negate the impact of this factor within an Irish context. A
further factor requiring consideration is treatment availability.
Taking part in clinical trials is likely to advantage trial participants
whereby they gain access to treatments that are new, innovative,
expensive and not available elsewhere especially within the
oncology setting [24].3.3.6. Time
A number of studies included in this review identiﬁed time as a
signiﬁcant inﬂuencing factor. The time commitment required to
participate in a clinical trial is identiﬁed as an important barrier to
participation. The time costs included the inconvenience of trial
related requirements and visits; travel; following speciﬁc regimens
and completing a daily diary log [6,9,42,43]. The time to arrange
transport was the greatest barrier for participation [14,26] and this
is likely to be due to the lack of clinical trials available in rural areas
[27]. A separate but related element of time was also identiﬁed and
E. Walsh, A. Sheridan / Contemporary Clinical Trials Communications 3 (2016) 23e3128this related to the time taken by staff recruiting study participants.
If recruitment practices involve clearly outline eligibility criteria
and allow for recruitment staff to spend sufﬁcient time and effort
on eligible candidates, potential health beneﬁts and associated
risks, participation rates can be increased effectively [38].
3.3.7. Altruism
Altruism or selﬂessness is described as the principle or practice
of concern for the welfare of others. It is frequently considered as a
core virtue in many cultures and is a central principle in many
religious traditions and secular worldviews. Altruism is also
considered to be the undertaking of good acts without the thought
of personal reward. Altruism was identiﬁed as a key factor which
positively inﬂuences participation in clinical trials. In the clinical
trial setting altruism is seen as an act for the betterment of mankind
[43]. Themost common explanations of altruismwithin this review
was the act of unselﬁshness for contribution to medicine and sci-
ence [7,8,10,19,25,30], and to help others, be it the community or
nursing care, family or future patients [8,9,16,19,23,38,42,44]. This
review identiﬁed that the act of altruism is most likely to be
observed within the haematology and oncology settings with it
occurring less prominently in settings such as cardiology, gastro-
intestinal diseases and diabetes. The prominence of altruism in a
speciﬁc setting may be linked to the nature and progression of
disease. Those entering haematology or oncology trials are likely to
be inﬂuenced signiﬁcantly by the life limiting or life threatening
nature of their condition, may view the trial as a means to
contribute to treatment advances as well as obtaining some sense
of personal meaning and purpose within their illness. There is no
reason to assume that altruism as a positive indicator for partici-
pation in clinical trials would differ in impact upon patients
worldwide by it’s very deﬁnition.
3.3.8. Communication
Communication was an important variable when looking at
increasing participation into clinical trials. There are a variety of
positive and negative inﬂuences identiﬁed when considering
communication as a variable [43] and language, knowledge, un-
derstanding and misconception are among the collective terms
used to identify communication factors. Knowledge and under-
standing are dependent upon the information provided to partici-
pants. Having a lack of information, along with a lack of
understanding of clinical trials and concerns about the effective-
ness of clinical trials [44] leads to negative inﬂuences giving further
cause for non-participation. If the information provided is adequate
and user friendly [39], and is provided in the relevant language
[43,45], it is likely to result in positively inﬂuencing participants to
participate in clinical trials. Furthermore, factors relating to lan-
guage [21,34,43,45,46], as well as those associated with visual and
auditory impairment combine to negatively impact the consent
process [46], thus reducing the likelihood of individuals partici-
pating in clinical trials.
Communication is also impacted by how information about
clinical trials is presented and advertised. Information which is
provided in a newsletter format or publicised by themedia resulted
in patients being more willing to participate in the clinical trial as
well as being likely to give potential participants more conﬁdence
in the research being undertaken [18,41,44].
This review identiﬁed a number of misconceptions related to
understanding and knowledge about clinical trials. Clinical trials
were perceived as a potential threat to participants health [21] and
partaking in the trial was viewed as the last option [45]; doctors
and clinicians were considered to have more interest in the trial
than the person per se and the individual perceived they had less
say in their carewhen participating in trial [25]. Issues pertaining tounder-representation of ethnic minorities were also identiﬁed with
some potential participants considering that clinical trials are
designed for a pre-dominantly Caucasian population with ﬁndings
positively biased towards the white population [22]. Providing
sufﬁcient time to address these perceptions further may result in
potential participant becoming more informed and thus result in a
greater uptake in participation in clinical trials. Awareness of the
nature and types of misconceptions among potential trial partici-
pants is essential as understanding these will assist researchers to
accurately inform and re-educate potential participants [19,47] and
by doing so increase recruitment. Within Ireland clinical trials are
identiﬁed though internet base platforms and through word of
mouth by consultants. If Ireland was to utilise resources like other
countries worldwide for example they used advertisement or
increased media via news letters, this may have a more positive
inﬂuence on patients for participation within Ireland as greater
knowledge would be accessible about the different trials and it is
anticipated that communication would no longer be a deterrent.
3.3.9. Physician inﬂuence
Sixteen of the papers reviewed discussed Physician inﬂuence
and identiﬁed it to be one of the most provocative variables in
inﬂuencing patient participation in clinical trials
[7,11,18,21,23e25,27e30,36,44,48]. Physician recommendation was
identiﬁed as a variable inﬂuencing patient participation in seven of
the studies reviewed, with a further ﬁve identifying physicians as
having a positive impact on participation while two identiﬁed
physicians acting as a discouragement to patient participation.
Patients appear to be more inﬂuenced to take part if they have a
good relationship with and trusts the physician [18,28,36]; the
physician is experienced, involved in the clinical trial and is repu-
table [14,28,29,49]. Patients are more likely to decline participation
if the physician discouraged due to either their dissatisfaction with
trial design, or the physician's feelings of responsibility if a patient
suffered as a result of partaking in the trial [27], appears to have
more interest in the trial than patient care [25], and patients have a
lack of conﬁdence in the physician [11]. The nature of the Irish
healthcare system means that patients will have a single primary
physician, as opposed to multiple physicians in other countries
health care settings such as United Kingdom. We would anticipate
this having a positive impact upon patients' willingness to partic-
ipate in Clinical Trials in Ireland as they will build trusted re-
lationships with their physician.
3.3.10. Demographics
This part played by patient demographics, as a predicting vari-
able for participating in clinical trials, continues to be debated.
Demographic variables considered inﬂuential included the social
and economic characteristics of a speciﬁc population as well as
gender, race and ethnicity, sexual orientation, age, religion and
income level [2,9,13,15,20,26,31,35e38,40,46,49,50].
In clinical trials and any research, it is important to have true
representation of the overall population. This includes minority
groups, which incorporate women and ethnic communities as
observed throughout this literature [46]. Despite the perceived
importance of these groups, only two of the articles within this
review focus on these [2,36].
One demographic characteristic, that of age, and whether or not
it was a predictor for patient participation was identiﬁed as a
contentious issue within the literature reviewed. This review
identiﬁed that older groups were considered as less willing to
participate [49,50]. However it may well that be older people are
less likely to be invited to participate due to a perception of po-
tential cognitive impairment or they may be seen as less likely to
comply with rigorous protocols thus potentially jeopardising the
E. Walsh, A. Sheridan / Contemporary Clinical Trials Communications 3 (2016) 23e31 29study outcomes. Nevertheless, this review also identiﬁed that older
people felt that they should not be judged by their age, and that
when considering a clinical trial, they should be looked at as an
individual in their entirety [40]. While age was identiﬁed as
potentially controversial, the issue of religion was only addressed
within one study and in this case it was viewed as exerting a
negative inﬂuence on participation, as the participants believed
their fate was in the hands of God [37].
However, while demographics and the likelihood of the
different characteristics to predict participation in clinical trials are
identiﬁed as important, some disagreement continues to exist as to
the true part demographics play in patients' willingness to partic-
ipate in clinical trials. According to Kasner [9] demographics were
not identiﬁed as being inﬂuential in the decision to participate in
clinical trials and Biedrzycki [13] found that socio-demographic
factors including age, race and gender, and had no signiﬁcant
impact on the decision to participate in clinical trials.
4. Discussion
There is an absence of Irish data about the factors which operate
to inﬂuence patient participation in clinical trials. However, data
originating in other international clinical trial facilities have sought
to identify the factors that facilitate and or inhibit patient partici-
pation in clinical trials both from a patient and a health care
perspective and with some exceptions, these are likely to be
transferable to the Irish context. One clinical research facility
located in Ireland serves a population of over one million, and the
numbers of clinical trial participation was less than half of one
percent of the 250,000 patients directly treated in the associated
hospitals. While it is unknownwhether these patients were eligible
for ongoing studies within this facility, the review presented in this
paper was undertaken to address the factors that contribute to
participation of patients. This narrative literature review has
identiﬁed that the vast majority of literature relating to participa-
tion in clinical trials emanates predominantly from high income
countries, with 63% originating from the USA. It is a notable ﬁnding
that no studies for inclusion in this reviewwere identiﬁed from low
income or developing countries. Although the trials carried out are
global, and participants may be from low and middle income
countries, it is difﬁcult to identify if speciﬁc factors identiﬁed as
inﬂuencing patient participation in clinical trials in higher income
countries have the same relevance for participants in middle and
low income countries.
The review identiﬁed the primary factor inﬂuencing participa-
tion in clinical trials amongst patients was related to personal
factors and that these were collectively associated with obtaining a
form of personal gain through participation. The type of personal
gain identiﬁed was that related to receiving better or more treat-
ment and care.While it appears that, obtaining access to carewhich
would otherwise not be possible was particularly relevant in in-
surance based care systems such as the USA, it is also likely that
factor inﬂuences trial participation within the Irish context. While
obtaining access to care not otherwise available may be less inﬂu-
ential due to the Irish health systems broadly welfare based model
whereby citizens do not require private health insurance, getting
access to novel treatments with their perceived greater efﬁcacy
may be more inﬂuential. Personal gain also included obtaining
more positive outcomes. However, it is likely that personal gain is
mediated by other factors including the perception of personal risk
and fear as well as personal cost including time and ﬁnancial costs;
altruism, communication, physician inﬂuence, research process
and demographics.
Clinical research regulations mandate that the decision making
for clinical trial participation should be independent [13]. However,information giving is a signiﬁcant part of the trials process and
independent decision making may not be the preference for par-
ticipants who accept or decline participation in clinical trials. This
review has identiﬁed that patients are inﬂuenced to take part in
clinical trials based on their relationship with the physician. A
relationship perceived by a patients as good and trusting with the
physician is likely to result in participation. However, if relation-
ships were not perceived as good or if the physicianwas in any way
discouraging, a decline in invitation to participate was more likely.
Thus physician inﬂuence was identiﬁed as potentially the most
challenging variable in inﬂuencing patient participation. Within
the Irish context, regulation clearly states that the physician should
not coerce or unduly inﬂuence the patient to participate, and that
participants are the ﬁnal decision makers whether or not to
participate in trials [33], although this review clearly identiﬁes that
patients are inﬂuenced by the physician.
In the absence of Irish evidence, it is difﬁcult to estimate if po-
tential clinical trial participants experience these factors differently.
With regard to experience of risk, it is possible that within the Irish
context that this may be mediated by the inﬂuence of physicians
and other health professionals. In Ireland cultural norms pertaining
to the conduct of medical practice and professional e patient based
relationships are still largely based within a public welfare model.
The ideology underpinning this model of serving the poor, while
becoming less dominant, in reality still retains elements of pro-
fessional dominance and paternalism whereby signiﬁcant pro-
portions of patients, particularly those who are older, emanating
from lower socio-economic groups and with lower educational
levels abdicate responsibility for decision making to health care
professionals. Resultantly, these cultural differences in the conduct
of health care practice may affect the degree of inﬂuence of phy-
sicians and other health care professionals in that patients are more
likely to be guided by and accept the advice of the health pro-
fessionals in an unquestioning way when compared to patients in
health systems where patients by virtue of being required to pur-
chase health insurance operatemore as consumers of health care as
a product.
While striving to avoid any undue inﬂuence in decision making,
it is also important to note that physician communication may also
act as a deterrent to participation. Therefore it is critical to recog-
nise that physician attitude relating to decision making along with
their ability to communicate complex information in an appro-
priate manner will impact trial participation. Therefore, attention
to recruitment, information giving and consent strategies do
require further exploration to attempt to achieve a balanced
approach to recruitment of trial participants. If roles of patients as
potential participants as competent decision makers is under-
estimated by physicians, it is likely to result in less effective
communication about clinical trials.4.1. Limitations
This study has several limitations acknowledged by the authors.
The literature reviewwas limited to papers that were in the English
language, participants that were human and over eighteen years of
age. The search that was carried out was within a publication
period of 2003e2014 and articles included were required to be free
and in full text. Neither translators or paper articles costs were
feasible, due to ﬁnancial constraints and therefore limited the
study. Only four databases were used to carry out this literature
review, however these were seen as the most relevant databases
appropriate to this study.
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Despite its limitations, this review makes an important contri-
bution for clinicians and researchers in understanding the factors
which inﬂuence participation by patients or act to deter their
participation and this is identiﬁed from the perspective of patients.
Factors affecting patient participation in clinical trials has not as yet
been examined in Ireland and this review provides initial insight
into the decision making process of patients e having to make life
altering decisions while facing a chronic illness. To address the
absence of evidence within the Irish context, it is recommended
that future research should continue to focus on innovation in trial
methodologies and that these innovations incorporate exploration
of factors that act to both support and or deter patient participation
to enhance enrolment.
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